|
|
|
Dupilumab (13)
|
Dupixent®
|
Sanofi-Aventis Deutschland GmbH
|
Skin diseases
|
Chronic spontaneous urticaria, aged ≥ 2 years to < 12 years
|
n.d.
|
active procedure
|
|
|
|
Dupilumab (12)
|
Dupixent®
|
Sanofi-Aventis Deutschland GmbH
|
Skin diseases
|
Chronic spontaneous urticaria, aged ≥ 12 years
|
n.d.
|
active procedure
|
|
|
|
Dupilumab (11)
|
Dupixent®
|
Sanofi-Aventis Deutschland GmbH
|
Digestive system diseases
|
Eosinophilic oesophagitis, ≥ 1 year to < 12 years
|
530–590
|
100%
additional benefit not proven
|
|
|
|
Dupilumab (10)
|
Dupixent®
|
Sanofi-Aventis Deutschland GmbH
|
Respiratory system diseases
|
COPD
|
9,370
|
71%
Indication of
minor additional benefit
|
|
|
|
Dupilumab (7)
|
Dupixent®
|
Sanofi-Aventis Deutschland GmbH
|
Skin diseases
|
Prurigo nodularis
|
3,500–4,800
|
100%
Hint for
non-quantifiable additional benefit
|
|
|
|
Dupilumab (8)
|
Dupixent®
|
Sanofi-Aventis Deutschland GmbH
|
Digestive system diseases
|
Eosinophilic oesophagitis, ≥ 12 years, min. 40 kg
|
3,900–4,400
|
100%
additional benefit not proven
|
|
|
|
Dupilumab (9)
|
Dupixent®
|
Sanofi-Aventis Deutschland GmbH
|
Skin diseases
|
Atopic dermatitis, 6 months to 5 years
|
2,700–3,900
|
50%
Hint for
non-quantifiable additional benefit
|
|
|
|
Dupilumab (6)
|
Dupixent®
|
Sanofi-Aventis Deutschland GmbH
|
Respiratory system diseases
|
Asthma bronchiale, ≥ 6 until ≤ 11 years
|
150–860
|
100%
additional benefit not proven
|
|
|
|
Dupilumab (5)
|
Dupixent®
|
Sanofi-Aventis Deutschland GmbH
|
Skin diseases
|
Atopic dermatitis (AD), 6 to 11 years
|
9,700–14,100
|
100%
Hint for
non-quantifiable additional benefit
|
|
|
|
Dupilumab (4)
|
Dupixent®
|
Sanofi-Aventis Deutschland GmbH
|
Respiratory system diseases
|
Chronic rhinosinusitis with nasal polyps
|
10,500–12,600
|
100%
Indication of
considerable additional benefit
|
|
|
|
Dupilumab (2)
|
Dupixent®
|
Sanofi-Aventis Deutschland GmbH
|
Respiratory system diseases
|
Bronchial asthma, ≥ 12 years
|
17,560–54,300
|
100%
additional benefit not proven
|
|
|
|
Dupilumab (3)
|
Dupixent®
|
Sanofi-Aventis Deutschland GmbH
|
Skin diseases
|
Atopic dermatitis (AD), 12 to < 18 years
|
5,300–10,600
|
100%
Hint for
non-quantifiable additional benefit
|
|
|
|
Dupilumab (1)
|
Dupixent®
|
Sanofi-Aventis Deutschland GmbH
|
Skin diseases
|
Atopic dermatitis (AD)
|
52,000
|
100%
Indication of
considerable additional benefit
|
